• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kura Oncology, Inc. - Common Stock (NQ:KURA)

    12.21 -0.30 (-2.44%)
    Streaming Delayed Price Updated: 11:07 AM EDT, Sep 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 622,805
    Open 12.50
    Bid (Size) 12.21 (1,000)
    Ask (Size) 12.22 (500)
    Prev. Close 12.52
    Today's Range 12.15 - 12.61
    52wk Range 7.357 - 13.90
    Shares Outstanding 68,438,576
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026? ↗
    Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Kura Oncology (KURA) Q2 2026 Earnings Call Transcript ↗
    KOMZIFTI revenue surged 57% as new patient starts climbed 35%. 
    Via The Motley Fool
    Topics Earnings

    Performance

    YTD
    +18.2%
    +18.2%
    1 Month
    +24.0%
    +24.0%
    3 Month
    +38.6%
    +38.6%
    6 Month
    +31.9%
    +31.9%
    1 Year
    +50.1%
    +50.1%

    More News

    Read More
    News headline image
    Kura Oncology Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Kura Oncology (NASDAQ:KURA) Slips After Q1 Earnings Miss ↗
    Via Chartmill
    KURA ONCOLOGY INC (NASDAQ:KURA) Posts Q4 Revenue Beat but EPS Miss, Stock Falls in Pre-Market ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement ↗
    Via Stocktwits
    News headline image
    Kura Oncology Reports 50% Response Rate in RCC Combination Study ↗
    Via MarketBeat
    News headline image
    Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript ↗
    Via Benzinga
    Topics Earnings
    News headline image
    Kura Oncology Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
    From Kura Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
    From Kura Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
    From Kura Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Kura Scores A Big Win As FDA Approves Its New Leukemia Pill ↗
    Via Benzinga
    News headline image
    Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients ↗
    Via Stocktwits
    News headline image
    Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss ↗
    Via Chartmill
    News headline image
    Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial ↗
    Via Benzinga
    News headline image
    Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
    Via MarketMinute
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
    Via Benzinga
    News headline image
    This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Kura Oncology, Inc. - Common Stock publicly traded?
    Yes, Kura Oncology, Inc. - Common Stock is publicly traded.
    What exchange does Kura Oncology, Inc. - Common Stock trade on?
    Kura Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Kura Oncology, Inc. - Common Stock?
    The ticker symbol for Kura Oncology, Inc. - Common Stock is KURA on the Nasdaq Stock Market
    What is the current price of Kura Oncology, Inc. - Common Stock?
    The current price of Kura Oncology, Inc. - Common Stock is 12.21
    When was Kura Oncology, Inc. - Common Stock last traded?
    The last trade of Kura Oncology, Inc. - Common Stock was at 09/09/26 11:07 AM ET
    What is the market capitalization of Kura Oncology, Inc. - Common Stock?
    The market capitalization of Kura Oncology, Inc. - Common Stock is 835.98M
    How many shares of Kura Oncology, Inc. - Common Stock are outstanding?
    Kura Oncology, Inc. - Common Stock has 836M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.